Riskpilot← Back to searchSign inGet full accessLABORATORIET I NANNASGADE ApS
APSActiveCVR 26310075Vermundsgade 40C, st.Photographic activities · NACE 7420Est. 20017 employeeswww.silverab.dk
Revenue 2025
DKK 2,9M
+20% vs 2024
EBITDA margin
13.2%
-8% vs 2024
Equity ratio
0.0%
Financial strength
Net profit 2025
DKK 183K
-14% vs 2024
| Revenue | DKK 2,9M | +20% |
| EBITDA | DKK 381K | -8% |
| Net profit | DKK 183K | -14% |
| Total assets | DKK 2,5M | -10% |
| Equity | DKK 949 | +101% |
| Employees | 7 | — |
Legal name
LABORATORIET I NANNASGADE ApS
CVR number
26310075
Legal form
Anpartsselskab
NACE code
7420 · Photographic activities
Founded
1. november 2001
Share capital
DKK 125.000
Employees
7 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør
Company purpose
Selskabets formål er at drive virksomhed ved handel og industri
Address
Vermundsgade 40C, st.
Phone
+4535831504
Email
lab@silverlab.dk
Website
www.silverab.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 651 | 1.448 | 1.831 | 2.393 | 2.881 |
| Staff expenses | -633 | -1.840 | -1.815 | -1.979 | -2.500 |
| EBITDA | 18 | -392 | 16 | 414 | 381 |
| Depreciation & amort. | -0 | -145 | -145 | -145 | -145 |
| EBIT | 18 | -537 | -129 | 269 | 236 |
| Net financials | -13 | -6 | -2 | 5 | -0 |
| Profit before tax | 6 | -543 | -130 | 273 | 235 |
| Tax | 3 | -120 | -30 | 60 | 52 |
| Net profit | 3 | -423 | -101 | 213 | 183 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2.471 | 2.330 | 2.651 | 2.717 | 2.458 |
| Equity | 128 | -295 | -396 | -182 | 1 |
| Long-term debt | 2.132 | 1.922 | 2.487 | 2.253 | 1.823 |
| Short-term debt | 165 | 631 | 450 | 505 | 450 |
| Total debt | 2.298 | 2.553 | 2.937 | 2.758 | 2.274 |
EBITDA margin
13.2%
This company
15.8%
Market median
-16% vs market
20212025
Equity ratio
0.0%
This company
38.2%
Market median
-100% vs market
20212025
Return on equity
19306.2%
This company
18.4%
Market median
+104825% vs market
20212025
Net profit margin
6.4%
This company
8.1%
Market median
-21% vs market
20212025
Asset turnover
1.17×
This company
1.12×
Market median
+4% vs market
20212025
Debt / equity
2588.91×
This company
0.62×
Market median
-417466% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EE Management | Management | 2021 |
| Former (2) | ||
KM Management | Management | 2001 – 2001 |
PN Management | Management | 2001 – 2003 |
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
| Board of Directors | 2007 – 2009 | |
| Chairman | 2003 – 2017 | |
| Board of Directors | 2003 – 2017 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2021 | |
| Company | 100% | 100% | 2003 | |
| Individual | 100% | 100% | 2001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
EE81 Holding ApS
LABORATORIET I NANNASGADE ApS Board members of LABORATORIET I NANNASGADE ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Emil Eskesen | Management | 0 companies |
| Kim Madsen | Management | 0 companies |
| Pia Nissen | Management | 0 companies |
| Donald John Nekman | Board of Directors | 0 companies |
| Henrik Steen Petersen | Chairman | 0 companies |
| Thomas Steen Halkier | Board of Directors | 0 companies |